Abstract |
This study was purposed to analyse the clinical efficacy of transplantation of umbilical cord mesenchymal stem cells (UC-MSC) combined with haploidentical hematopoietic stem cells (haplo-HSCT) for patients with refractory/relapsed myeloid leukemia. The clinical data of 36 patients received transplantation of UC-MSC combined with haplo-HSCT from January 2007 to June 2013 were summarized retrospectively, the engraftment, GVHD and 2 years-overall survival (OS) were analysed. The results showed that the median times of neutrophil count>0.50×10(9)/L and platelet count>20×10(9)/L were 12.0 days and 14.0 days, respectively. Grade III to IV aGVHD occurred in 5 out of 36 patients (13.8%). cGVHD occurred in 12 out of 32 patients (37.5%) and extensive cGVHD occurred in 2 patients. Additionally, only 3 patients (8.3%) experienced relapse. The 2-year OS rate of patients was 76.9%. It is concluded that the transplantation of UC-MSC combined with haplo-HSCT has good therapeutic efficacy for patients with refractory/relapsed myeloid leukemia, and may be served as a therapeutic method especially for patients with high risk and without well matched donor.
|
Authors | Ya-Mei Wu, Yong-Bin Cao, Xiao-Hong Li, Li-Xin Xu, Zhou-Yang Liu, Bei Liu, Bei Yan, Xue-Liang Yang, Song-Wei Li, Wan-Ming DA, Chun-Ji Gao, Xiao-Xiong Wu |
Journal | Zhongguo shi yan xue ye xue za zhi
(Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Vol. 22
Issue 4
Pg. 1053-7
(Aug 2014)
ISSN: 1009-2137 [Print] China |
PMID | 25130827
(Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)
|
Topics |
- Adolescent
- Adult
- Child
- Child, Preschool
- Cord Blood Stem Cell Transplantation
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Myeloid
(therapy)
- Male
- Mesenchymal Stem Cell Transplantation
- Middle Aged
- Retrospective Studies
- Transplantation, Homologous
- Treatment Outcome
- Young Adult
|